Vistagen Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, announcing preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder.
Key Highlights
- Preliminary positive OLE data: Vistagen disclosed preliminary positive data from the open-label extension ("OLE") portion of its PALISADE-4 Phase 3 study of fasedienol.
- Indication studied: Fasedienol is being evaluated for the acute treatment of social anxiety disorder.
- Planned FDA meeting: According to the filing, the company plans to meet with the U.S. Food and Drug Administration during the current quarter to discuss the potential regulatory path forward for fasedienol.
- Potential NDA path: The company disclosed its belief that its fasedienol development program "could support a potential New Drug Application submission to the FDA for the acute treatment of social anxiety disorder."
- OLE consistency: The company disclosed its belief that the PALISADE-4 OLE results "are consistent with, supportive of, or complementary to previously reported fasedienol clinical data."
- Press release attached: A copy of the press release dated September 22, 2026, was filed as Exhibit 99.1 to the report.
Vistagen Discloses PALISADE-4 Open-Label Extension Findings for Fasedienol
Vistagen Therapeutics, Inc. (NASDAQ:VTGN), a Nevada-incorporated biopharmaceutical company headquartered in South San Francisco, California, filed a Form 8-K on September 22, 2026, under Item 8.01 (Other Events). The filing announced that the company issued a press release on the same date to report preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 clinical study of fasedienol, which is under evaluation for the acute treatment of social anxiety disorder.
According to the filing, the preliminary findings from the OLE portion of PALISADE-4 include "indications of improvements observed over time by patients" and "indications of safety data." The company also disclosed its belief that the preliminary OLE data "support potential clinical meaningfulness." The filing further stated that the company believes the OLE results are consistent with and supportive of previously reported fasedienol clinical data, and that the findings are complementary to other fasedienol clinical studies.
The filing noted that the company plans to meet with the FDA during the current quarter to discuss the potential regulatory path forward for fasedienol. The company also disclosed its belief that its fasedienol development program could support a potential New Drug Application submission to the FDA. The filing contains forward-looking statements, which the company cautioned involve "known and unknown risks that are difficult to predict," and referenced its Quarterly Report on Form 10-Q for the period ended June 30, 2026, and its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, as sources for a fuller discussion of relevant risk factors. The report was signed by Shawn K. Singh, President and Chief Executive Officer.
What Was Disclosed
Vistagen filed an 8-K on September 22, 2026, reporting preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder, along with plans for an FDA meeting in the current quarter to discuss the regulatory path forward.



Please wait processing your request...